欧美最新另类人妖I国产成人av一区二区三区在线观看I九九热精品视频在线观看I国产精品日韩在线I激情av五月婷婷I日韩精品免费

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Pongo abelii Cullin-7 (CUL7), partial CSB-YP735806PYX
CSB-EP735806PYX
CSB-BP735806PYX
CSB-MP735806PYX
CSB-EP735806PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Major facilitator superfamily domain-containing protein 4 (MFSD4), partial CSB-YP735807PYX
CSB-EP735807PYX
CSB-BP735807PYX
CSB-MP735807PYX
CSB-EP735807PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii UNC93-like protein MFSD11 (MFSD11), partial CSB-YP735808PYX
CSB-EP735808PYX
CSB-BP735808PYX
CSB-MP735808PYX
CSB-EP735808PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii ADP-ribosylation factor-like protein 3 (ARL3) CSB-YP735809PYX
CSB-EP735809PYX
CSB-BP735809PYX
CSB-MP735809PYX
CSB-EP735809PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Autophagy-related protein 9A (ATG9A), partial CSB-YP735810PYX
CSB-EP735810PYX
CSB-BP735810PYX
CSB-MP735810PYX
CSB-EP735810PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii V-type proton ATPase subunit D (ATP6V1D) CSB-YP735811PYX
CSB-EP735811PYX
CSB-BP735811PYX
CSB-MP735811PYX
CSB-EP735811PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D (NAPEPLD) CSB-YP735812PYX
CSB-EP735812PYX
CSB-BP735812PYX
CSB-MP735812PYX
CSB-EP735812PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Kelch domain-containing protein 8B (KLHDC8B) CSB-YP735813PYX
CSB-EP735813PYX
CSB-BP735813PYX
CSB-MP735813PYX
CSB-EP735813PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Fumarylacetoacetate hydrolase domain-containing protein 2 (FAHD2) CSB-YP735814PYX
CSB-EP735814PYX
CSB-BP735814PYX
CSB-MP735814PYX
CSB-EP735814PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Cyclin-dependent kinase 18 (CDK18) CSB-YP735815PYX
CSB-EP735815PYX
CSB-BP735815PYX
CSB-MP735815PYX
CSB-EP735815PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii POC1 centriolar protein homolog B (POC1B) CSB-YP735816PYX
CSB-EP735816PYX
CSB-BP735816PYX
CSB-MP735816PYX
CSB-EP735816PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Probable RNA-binding protein EIF1AD (EIF1AD) CSB-YP735817PYX
CSB-EP735817PYX
CSB-BP735817PYX
CSB-MP735817PYX
CSB-EP735817PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Dual specificity protein phosphatase 3 (DUSP3) CSB-YP735818PYX
CSB-EP735818PYX
CSB-BP735818PYX
CSB-MP735818PYX
CSB-EP735818PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Mediator of RNA polymerase II transcription subunit 6 (MED6) CSB-YP735819PYX
CSB-EP735819PYX
CSB-BP735819PYX
CSB-MP735819PYX
CSB-EP735819PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii General transcription factor 3C polypeptide 2 (GTF3C2), partial CSB-YP735820PYX
CSB-EP735820PYX
CSB-BP735820PYX
CSB-MP735820PYX
CSB-EP735820PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii CDC42 small effector protein 1 (CDC42SE1) CSB-YP735821PYX
CSB-EP735821PYX
CSB-BP735821PYX
CSB-MP735821PYX
CSB-EP735821PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Centrosomal protein of 70 kDa (CEP70), partial CSB-YP735822PYX
CSB-EP735822PYX
CSB-BP735822PYX
CSB-MP735822PYX
CSB-EP735822PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Juxtaposed with another zinc finger protein 1 (JAZF1) CSB-YP735823PYX
CSB-EP735823PYX
CSB-BP735823PYX
CSB-MP735823PYX
CSB-EP735823PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii Vesicular, overexpressed in cancer, prosurvival protein 1 (VOPP1), partial CSB-YP735824PYX
CSB-EP735824PYX
CSB-BP735824PYX
CSB-MP735824PYX
CSB-EP735824PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pongo abelii S1 RNA-binding domain-containing protein 1 (SRBD1), partial CSB-YP735825PYX
CSB-EP735825PYX
CSB-BP735825PYX
CSB-MP735825PYX
CSB-EP735825PYX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.practicalworld.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>



×